Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.73 |
| ▸ | HTR1B | P28222 | 11/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | HTR1F | P30939 | 2/20 | 0.54 |
| ▸ | NMT2 | O60551 | 1/20 | 0.54 |
| ▸ | NMT1 | P30419 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 13/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7478523 | 0.87 | HTR1D (0.60) | RORCHTR1BHTR1AHTR1FNMT2 | |
| SCHEMBL17495505 | 0.85 | RORC (1.00) | RORCHTR1BHTR1AHTR1F | |
| SCHEMBL17495501 | 0.84 | RORC (0.75) | RORCHTR1BHTR1AHTR1FHTR1D | |
| SCHEMBL17495532 | 0.84 | RORC (0.75) | RORCHTR1BHTR1AHTR1FHTR1D | |
| SCHEMBL17495450 | 0.84 | RORC (0.79) | RORCHTR1BHTR1AHTR1FHTR1D | |
| SCHEMBL7483539 | 0.83 | RORC (0.69) | RORCHTR1BHTR1AHTR1FHTR1D | |
| SCHEMBL20393357 | 0.83 | RORC (0.73) | RORCHTR1BHTR1AHTR1FHTR1D | |
| SCHEMBL7483530 | 0.82 | RORC (0.68) | RORCHTR1BHTR1AHTR1FHTR1D | |
| SCHEMBL7482668 | 0.81 | HTR1D (0.76) | HTR1BHTR1AHTR1FNMT2NMT1 | |
| SCHEMBL17495507 | 0.80 | RORC (0.74) | RORCHTR1BHTR1AHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180282304-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3027603-B1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3027603-A2 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282304-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | RORC 1/4885HTR1B 3631/4885HTR1A 3780/4885 |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | RORC 1/4885HTR1B 3631/4885HTR1A 3780/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | RORC 1/4885HTR1B 3631/4885HTR1A 3780/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | RORC 1/4885HTR1B 3631/4885HTR1A 3780/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | RORC 1/4885HTR1B 3631/4885HTR1A 3780/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | RORC 1/4885HTR1B 3631/4885HTR1A 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.